Abigail Beaney

Abigail Beaney is a journalist who covers the pharmaceutical industry and clinical trials. Her work often focuses on groundbreaking treatments and drug development, including psychedelics as potential therapies for mental health conditions. Abigail has reported on various clinical trial results, regulatory updates, and company developments in the pharmaceutical sector. She keeps track of emerging trends and key players in the industry to provide accurate and insightful coverage of this dynamic field.

100%

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

New HIV Prevention Drug Lenacapavir: Potential Price Drop to $40 per Year if Generics Allowed

New HIV Prevention Drug Lenacapavir: Potential Price Drop to $40 per Year if Generics Allowed

Broke On: Tuesday, 23 July 2024 New research suggests that the cost of producing Lenacapavir, a highly effective HIV prevention drug, could be as low as $40 per person a year if generic versions are allowed for manufacturing. This contrasts with its current price of over $40,000 per person a year in various countries. UNAIDS is urging Gilead Sciences to make the drug more accessible to people in developing countries and allow generic manufacturing through the UN-backed Medicines Patent Pool.